PMID- 26517511 OWN - NLM STAT- MEDLINE DCOM- 20160927 LR - 20191210 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 6 IP - 39 DP - 2015 Dec 8 TI - High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival. PG - 42362-71 LID - 10.18632/oncotarget.5705 [doi] AB - The incidence and prognostic role of MYC and BCL2 rearrangements in mature B-cell lymphomas have been extensively studied, except the infrequent mantle cell lymphoma (MCL). Here, we analyzed the MYC and BCL2 abnormalities and other cytogenetic aberrations by fluorescence in situ hybridization (FISH) in 50 MCL patients with bone marrow involvement. Eighteen patients (36.0%) had MYC gains and/or amplifications, and twelve patients (24.0%) had BCL2 gains and/or amplifications. Among the 18 patients with MYC abnormality, four had simultaneous MYC translocations, but no BCL2 translocation was detected among patients with BCL2 abnormality. Only two patients (4.0%) had both MYC and BCL2 abnormalities. The patients with a MYC abnormality had a significantly higher tumor burden, a higher percentage of medium/high risk MIPI group and genomic instability compared to those without this abnormality. However, no significant difference was observed between patients with or without a BCL2 abnormality in terms of clinical and cytogenetic factors. Patients with a MYC abnormality had poorer progress-free survival (PFS) (9.0 vs. 48.0 months, p = .000) and overall survival (OS) (12.0 vs. 94.5 months, p = .000), but the presence of a BCL2 abnormality did not significantly influence either PFS or OS. In multivariate analysis, the MYC abnormality was the independent adverse factor for both PFS and OS, and intensive chemotherapy did not improve the outcome of these patients. Thus, the presence of a MYC but not BCL2 abnormality predicted the poor survival of MCL patients, and a new treatment strategy should be developed for these patients. FAU - Yi, Shuhua AU - Yi S AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Zou, Dehui AU - Zou D AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Li, Chengwen AU - Li C AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Zhong, Shizhen AU - Zhong S AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Chen, Weiwei AU - Chen W AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Li, Zengjun AU - Li Z AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Xiong, Wenjie AU - Xiong W AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Liu, Wei AU - Liu W AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Liu, Enbin AU - Liu E AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Cui, Rui AU - Cui R AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. AD - Department of Hematology, Tianjin First Center Hospital, Tianjin, China. FAU - Ru, Kun AU - Ru K AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Zhang, Peihong AU - Zhang P AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Xu, Yan AU - Xu Y AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - An, Gang AU - An G AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Lv, Rui AU - Lv R AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Qi, Junyuan AU - Qi J AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Wang, Jianxiang AU - Wang J AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Cheng, Tao AU - Cheng T AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. FAU - Qiu, Lugui AU - Qiu L AD - State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (MYC protein, human) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Proto-Oncogene Proteins c-myc) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cell Line, Tumor MH - Disease-Free Survival MH - Female MH - Gene Amplification MH - Gene Rearrangement MH - Humans MH - In Situ Hybridization, Fluorescence/*methods MH - Lymphoma, Mantle-Cell/drug therapy/*genetics/pathology MH - Male MH - Middle Aged MH - Outcome Assessment, Health Care MH - Prognosis MH - Proto-Oncogene Proteins c-bcl-2/*genetics MH - Proto-Oncogene Proteins c-myc/*genetics MH - Translocation, Genetic PMC - PMC4747232 OTO - NOTNLM OT - BCL2 OT - MYC OT - P53 OT - mantle cell lymphoma OT - prognosis COIS- CONFLICTS OF INTEREST The authors have no conflicts of interest to declare. EDAT- 2015/10/31 06:00 MHDA- 2016/09/28 06:00 PMCR- 2015/12/08 CRDT- 2015/10/31 06:00 PHST- 2015/05/09 00:00 [received] PHST- 2015/10/13 00:00 [accepted] PHST- 2015/10/31 06:00 [entrez] PHST- 2015/10/31 06:00 [pubmed] PHST- 2016/09/28 06:00 [medline] PHST- 2015/12/08 00:00 [pmc-release] AID - 5705 [pii] AID - 10.18632/oncotarget.5705 [doi] PST - ppublish SO - Oncotarget. 2015 Dec 8;6(39):42362-71. doi: 10.18632/oncotarget.5705.